CDEC final recommendation. Tiotropium bromide (Spiriva respimat -- Boehringer Ingelheim Canada Ltd.) : indication : chronic obstructive pulmonary disease.

CDEC final recommendation. indication : chronic obstructive pulmonary disease. Tiotropium bromide (Spiriva respimat -- Boehringer Ingelheim Canada Ltd.) :

The Canadian Drug Expert Committee (CDEC) recommends that tiotropium bromide (Spiriva Respimat) be listed for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphys...

Full description

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK534070/
Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2015
Series:Common drug review clinical review report.
Subjects:
Pulmonary Disease, Chronic Obstructive > drug therapy.
Tiotropium Bromide > therapeutic use.
Tiotropium Bromide > economics.
Treatment Outcome.
Cost-Benefit Analysis.
Canada.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK534070/
Full text

Similar Items